Terminated PHASE1 INTERVENTIONAL 6-arm NCT05109650

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6026 as Monotherapy and in Combination With BAT1308 in Patients With Advanced Solid Tumours

Sponsor: Bio-Thera Solutions

Conditions Advanced Solid Tumour

Interventions BAT1308 BAT6026

Updated 5 times since 2021 Last updated: Aug 7, 2025 Started: Feb 28, 2022 Primary completion: Mar 23, 2023 Completion: Feb 2, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily

Other terminated trials from Bio-Thera Solutions

See all terminations from Bio-Thera Solutions

Listed as NCT05109650, this PHASE1 trial focuses on Advanced Solid Tumour and remains terminated or withdrawn. Sponsored by Bio-Thera Solutions, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jun 2023 — Jul 2024 [monthly]

Terminated PHASE1

Status: Not Yet Recruiting → Terminated
Dec 2021 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bio-Thera Solutions

Data source: Bio-Thera Solutions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kogarah, Australia
• Sydney, Australia